Vyvanse Monitoring Schedule: Labs & Exams Your Prescriber Should Order

How Vyvanse Works: Mechanism and Duration

Vyvanse is a prodrug. After oral ingestion, intestinal and red-blood-cell enzymes cleave the lysine carrier from lisdexamfetamine to release d-amphetamine, the active moiety. This hydrolysis step is rate-limiting and produces a smoother plasma concentration curve than immediate-release amphetamine salts, with a Tmax for d-amphetamine of approximately 3.8 hours and a half-life of roughly 10 to 13 hours in adults [FDA label, NDA 021977].

Why the Prodrug Design Matters for Monitoring

Because bioavailability depends on enzymatic hydrolysis rather than gastric pH or food, plasma levels are more predictable than with mixed amphetamine salts. That predictability simplifies therapeutic drug monitoring. You do not need routine serum amphetamine levels unless you suspect non-adherence or toxicity.

The d-amphetamine released from Vyvanse acts by reversing the dopamine transporter (DAT) and norepinephrine transporter (NET), flooding synaptic clefts in the prefrontal cortex and striatum with catecholamines. DAT reversal accounts for the drug's efficacy in ADHD; NET reversal explains most of its cardiovascular side effects, including increased heart rate and blood pressure [1].

Duration of Action and Dosing Windows

Wigal et al. (J Atten Disord, 2017; N=117 children aged 6 to 12) demonstrated statistically significant ADHD symptom reduction across a 13-hour laboratory school day at lisdexamfetamine doses of 30 mg, 50 mg, and 70 mg, with effect sizes remaining consistent from 2 hours through 13 hours post-dose (P<0.001 vs. Placebo at all time points) [1]. That 13-hour window is why the FDA label specifies morning dosing and why afternoon or evening administration is contraindicated.

Baseline Evaluation Before the First Dose

Every patient starting Vyvanse needs a structured baseline workup. This is not optional documentation. It establishes the reference values against which every future monitoring visit is compared.

Cardiovascular Baseline

Measure resting blood pressure and heart rate after the patient has been seated for at least 5 minutes. Record both arms on the first visit. A single elevated reading does not disqualify a patient, but two readings of systolic BP above 135 mmHg or diastolic above 85 mmHg warrant cardiology clearance before starting a stimulant [2].

Obtain a 12-lead ECG if the patient or any first-degree relative has a personal history of: structural heart disease, arrhythmia, long-QT syndrome, or sudden cardiac death before age 40. The American Heart Association recommends this evaluation specifically for children and adolescents being considered for stimulant therapy [2].

Listen for murmurs. Hypertrophic cardiomyopathy is a relative contraindication to stimulant use, and a new murmur at baseline is an indication for echocardiography before proceeding.

Metabolic and Laboratory Baseline

Order the following at the baseline visit:

• Complete blood count (CBC) with differential. Amphetamines can produce mild leukopenia and, rarely, thrombocytopenia with chronic use [3].
• Comprehensive metabolic panel (CMP). Establishes hepatic and renal function. Severe renal impairment (GFR <30 mL/min/1.73 m²) reduces lisdexamfetamine clearance by approximately 34%, and dose capping at 50 mg/day is recommended [4].
• Thyroid-stimulating hormone (TSH). Undiagnosed hyperthyroidism can mimic ADHD and potentiate amphetamine-induced tachycardia.
• Urine drug screen (UDS). Establishes a sober baseline, documents pre-existing substance use, and protects the prescriber legally.

Psychiatric and Symptom Baseline

Score the patient on a validated instrument before the first dose. For ADHD, use the ADHD Rating Scale 5th edition (ADHD-RS-5), which provides separate inattention and hyperactivity-impulsivity subscales [5]. For binge eating disorder (BED), use the Yale-Brown Obsessive Compulsive Scale modified for binge eating (YBOCS-BE) [6]. Baseline scores let you calculate meaningful percent reductions at follow-up, which is the standard of care in both FDA indication domains.

Growth Anthropometrics in Pediatric Patients

Weigh and measure every child and adolescent at baseline. Plot on the appropriate CDC growth chart (boys or girls, 2 to 20 years) and record the percentile [7]. Stimulant-associated growth suppression averages 1 to 2 cm per year of height and 1 to 3 kg of body weight in the first 1 to 3 years of treatment, based on a meta-analysis of 22 controlled trials (N=2,897) published in Pediatrics [8]. You cannot identify suppression without a documented starting point.

The 4-Week Follow-Up Visit

The first post-initiation visit should occur 4 weeks after starting Vyvanse or 4 weeks after any dose change. Dose titration in ADHD begins at 30 mg/day and increases in 10-mg or 20-mg increments at weekly intervals; each new target dose warrants its own 4-week checkpoint if the prescriber does not titrate weekly.

What to Check at 4 Weeks

Recheck sitting blood pressure and heart rate. A mean increase of 2 to 4 mmHg systolic and 3 to 6 bpm resting heart rate is common with amphetamine-class drugs and is generally acceptable [2]. An increase of more than 10 mmHg systolic or more than 15 bpm sustained over two readings is a reason to reduce the dose or consider co-prescribing a beta-blocker after cardiology consultation.

Re-administer the ADHD-RS-5 or YBOCS-BE. A 30% reduction from baseline score is the standard threshold for "responder" status used in the Vyvanse key trials [9]. Patients who do not meet this threshold by week 4 at the maximum tolerated dose may need a diagnostic re-evaluation or a medication class change.

Ask specifically about:

• Appetite suppression and meal timing
• Sleep onset latency (Vyvanse's 13-hour duration can push sleep onset past midnight if taken after 9 a.m.)
• Mood lability, particularly late-afternoon "rebound" irritability as d-amphetamine levels decline
• Cardiovascular symptoms: palpitations, chest discomfort, exertional dyspnea

Weigh pediatric patients at every visit. A 4-week weight loss exceeding 5% of baseline body weight is a clinical signal to discuss appetite management strategies and, if severe, to lower the dose [8].

Quarterly Monitoring: Months 3, 6, and 9

After the 4-week visit, move to a quarterly schedule for the first year. Each quarterly visit should include all the elements below.

Cardiovascular Re-Assessment

Measure BP and HR at every quarterly visit. The FDA label for lisdexamfetamine carries a boxed warning for cardiovascular events, and the prescriber's record must document that cardiovascular status was evaluated at each renewal [4]. No new labs are needed for cardiovascular monitoring at quarterly visits unless the BP or HR is elevated.

Symptom Ratings

Re-score the ADHD-RS-5 or YBOCS-BE. Document the percent change from the established baseline score. For adults with BED, the FDA-approved dose range is 50 to 70 mg/day, and trials supporting approval showed a 79.3% reduction in binge eating days per week on 70 mg vs. 44.7% on placebo (P<0.001, N=383, Study 1 of NDA 021977) [10].

Controlled Substance Risk Assessment

Query the Prescription Drug Monitoring Program (PDMP) at every renewal. Vyvanse is Schedule II under the Controlled Substances Act, meaning no refills are permitted and each prescription requires a new PDMP query in most states [11]. Document the query result in the chart. Look for overlapping controlled-substance prescriptions from other providers. A urine drug screen is appropriate at a minimum of once per year and any time diversion or non-adherence is suspected [12].

The table below summarizes the complete monitoring framework across all visit intervals.

| Monitoring Parameter | Baseline | 4 Weeks | Every 3 Months (Yr 1) | Every 6 Months (Yr 2+) | |---|---|---|---|---| | Blood pressure + heart rate | Yes | Yes | Yes | Yes | | Weight | Yes | Yes | Yes | Yes | | Height (pediatric) | Yes | No | Yes | Yes | | CDC growth chart plot | Yes | No | Yes | Yes | | CBC with differential | Yes | No | Annually | Annually | | Comprehensive metabolic panel | Yes | No | Annually | Annually | | TSH | Yes | No | If symptomatic | If symptomatic | | Urine drug screen | Yes | Optional | Once/year minimum | Once/year minimum | | PDMP query | Yes | Yes | Yes (each Rx) | Yes (each Rx) | | ADHD-RS-5 or YBOCS-BE | Yes | Yes | Yes | Yes | | ECG (cardiac history) | Yes | Only if new Sx | Only if new Sx | Only if new Sx | | Psychiatric symptom review | Yes | Yes | Yes | Yes |

Semi-Annual Monitoring: Year Two and Beyond

Once a patient has been stable on Vyvanse for 12 months, monitoring intervals can extend to every 6 months for most parameters. Annual laboratory work (CBC, CMP) remains standard.

Growth Monitoring Beyond Year One

A Pediatrics meta-analysis (N=2,897 across 22 trials) found that height suppression was most pronounced in years 1 and 2, with partial catch-up growth observed when stimulants were discontinued or during planned drug holidays [8]. Clinicians should compare each visit's height percentile to the previous one, not just to population norms, because a child can be at the 50th percentile and still be falling across percentile lines.

Annual drug holidays, typically over the summer for school-age children, allow reassessment of whether the medication is still needed and permit recovery of any suppressed growth velocity. The decision is individualized: a child with severe ADHD impairing safety may not be a good candidate for a holiday [13].

Long-Term Cardiovascular Surveillance

Amphetamine exposure over years increases sympathetic tone. A retrospective cohort study (N=150,359 adults) published in JAMA Psychiatry found that long-term stimulant use was associated with a 19% increased risk of hypertension over 5 years compared with non-use (HR 1.19; 95% CI 1.10 to 1.28) [14]. At 6-month visits for patients on Vyvanse for more than 2 years, consider a 24-hour ambulatory blood pressure monitor (ABPM) if in-office readings trend upward, because white-coat effects can obscure true hypertension or mask masked hypertension.

Special Populations: Adjusted Monitoring Protocols

Pregnancy and Breastfeeding

Vyvanse is not recommended during pregnancy. The FDA label classifies it as Category C based on animal data showing fetal harm at clinically relevant doses [4]. If a woman of reproductive age is prescribed Vyvanse, document a pregnancy test at baseline and discuss contraception. Amphetamines are excreted in breast milk at a milk-to-plasma ratio of approximately 2.8 to 7.5, delivering estimated infant doses of 2% to 13% of the weight-adjusted maternal dose [15]. Breastfeeding is generally discouraged.

Renal Impairment

As noted above, GFR <30 mL/min/1.73 m² requires dose capping at 50 mg/day. Patients with end-stage renal disease should not receive Vyvanse doses above 50 mg/day; dialysis removes negligible amounts of lisdexamfetamine or d-amphetamine [4]. Monitor serum creatinine and eGFR annually in all adult patients and more frequently if there is a prior history of renal disease.

Adults Over Age 65

Older adults metabolize amphetamines more slowly and have higher baseline cardiovascular risk. No Vyvanse trials have enrolled adults over 65 in sufficient numbers to establish age-specific dosing or monitoring thresholds [4]. Apply conservative cardiovascular thresholds: hold or reduce the dose if resting HR exceeds 90 bpm or if systolic BP exceeds 130 mmHg on two consecutive readings.

When to Stop, Hold, or Refer

Clear criteria guide when Vyvanse must be paused or discontinued permanently.

Hold the medication and refer to cardiology if:

• Resting systolic BP exceeds 150 mmHg or diastolic BP exceeds 95 mmHg on two readings 1 week apart
• New arrhythmia detected (confirmed on ECG or wearable monitor)
• Exertional chest pain, syncope, or near-syncope occurs
• A new cardiac murmur is found on auscultation

Discontinue permanently and document if:

• Structural cardiac defect is identified that was not present at baseline
• Signs of psychosis, mania, or severe aggression emerge (these are listed in the FDA label as reasons for discontinuation) [4]
• Evidence of diversion: PDMP shows supply discrepancy, or pill count reveals stockpiling

Refer to psychiatry if:

• Mood symptoms develop or worsen significantly (ADHD and bipolar disorder co-occur in roughly 20% of adults) [16]
• The ADHD-RS-5 score does not improve by at least 20% after 8 weeks at maximum tolerated dose
• The patient reports recreational use or requests early refills on two or more occasions

What Patients Should Track Between Visits

Patients are active participants in monitoring. Ask them to record:

• Morning blood pressure using a validated home cuff (validated per the American Medical Association's validated device list) [17]
• Daily appetite rating on a 1-to-10 scale, with a note of whether they ate at least two meals
• Sleep onset time each night
• Any missed doses, because uneven adherence can confound clinic readings

A simple symptom diary completed for 7 days before each visit gives the clinician far more signal than a single-point-in-time clinic assessment. The American Academy of Pediatrics' 2019 ADHD Clinical Practice Guideline explicitly recommends structured parent and teacher rating scales at every medication visit, not just at initiation [13].

As the AAP 2019 guideline states: "For children and adolescents with ADHD who are treated with medication, clinicians should evaluate and monitor for treatment-emergent adverse effects, including changes in heart rate, blood pressure, height, weight, and any new psychiatric symptoms." [13]

Interpreting Lab Results: Specific Thresholds

Not every abnormal value requires action. The table below gives actionable thresholds based on FDA labeling [4], AHA recommendations [2], and published pharmacokinetic data [3].

| Lab or Vital | Normal Range | Concern Threshold | Action | |---|---|---|---| | Systolic BP | <120 mmHg | 135 to 149 mmHg | Lifestyle counseling, recheck in 4 weeks | | Systolic BP | <120 mmHg | ≥150 mmHg (×2) | Hold Vyvanse, cardiology referral | | Resting HR | 60 to 100 bpm | 101 to 110 bpm | Reduce dose, recheck in 2 weeks | | Resting HR | 60 to 100 bpm | >110 bpm (×2) | Hold Vyvanse, ECG, cardiology | | eGFR | ≥60 mL/min | 30 to 59 mL/min | Cap dose at 70 mg, monitor quarterly | | eGFR | ≥60 mL/min | <30 mL/min | Cap dose at 50 mg, monthly eGFR | | WBC | 4,500 to 11,000/µL | <3,500/µL | Repeat CBC, hold if confirmed | | Weight loss | <5% from baseline | 5% to 10% in 4 weeks | Nutrition consult, appetite management | | Weight loss | <5% from baseline | >10% in 4 weeks | Dose reduction, consider drug holiday |